Ionis Pharmaceuticals’ antisense oligonucleotide drug, olezarsen (Tryngolza), demonstrated robust efficacy and safety in pivotal Phase III CORE and CORE2 trials for severe hypertriglyceridemia. The therapy significantly reduced fasting triglyceride levels by up to 72% compared to placebo and lowered acute pancreatitis events by 85%. It showed a favorable safety profile, with injection site reactions being the most common side effect and a high continuation rate into an open-label extension study. These results position Tryngolza for label expansion, moving beyond its initial approval for rare familial chylomicronemia syndrome to address a broader patient population with severe hypertriglyceridemia, which is growing due to rising obesity and diabetes rates. This advance could establish Ionis as a key player in the multibillion-dollar lipid-lowering market.